23andMe Inc., the Silicon Valley firm known for its ancestry DNA tests, has licensed an antibody it developed to treat inflammatory diseases to Spanish drugmaker Almirall SA.
The deal, announced by Almirall in a filing with Spanish regulators on Thursday, marks the first time that 23andMe has licensed a drug compound that it has developed itself.
